# Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer

> **NCT03053544** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 15 (actual)

## Conditions studied

- Rectal Neoplasm Carcinoma in Situ Adenocarcinoma

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03053544
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-08
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053544, "Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03053544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*